Compare DexCom, Inc. (DXCM) vs Oracle Corporation (ORCL) Price & Performance

DexCom (DXCM) trades at $74.12, down 2.92% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent revenue growth, expanding profit margins, and a track record of beating earnings estimates. Recent regulatory approvals for its G7 15-day CGM in Canada and pediatric clearance for its Stelo OTC system in the U.S. highlight ongoing product expansion.

The investment thesis centers on DexCom's leadership in the growing CGM market, supported by strong financial execution and analyst optimism. Key risks include competition from Abbott, the commercial unproven nature of expansion into non-insulin Type 2 diabetes patients, and potential disruption from GLP-1 drug adoption. The consensus price target of $84.33 suggests ~14% upside from current levels.

Oracle Corporation (ORCL) is trading at $127.96, down 2.96% in the last session, amid mixed technical signals with a bearish moving average trend but bullish oscillator readings. Fundamentally, the company shows strong profitability with 65.82% gross margins and 25.37% net income margins, supported by consistent earnings beats in recent quarters. Revenue growth has been steady, reaching $57.40B in 2025, with analyst consensus strongly favoring a Buy rating (65.12%) and a $259 price target representing significant upside potential.

The outlook for Oracle remains positive driven by AI infrastructure demand and strategic partnerships, though risks include high debt levels ($92.64B total debt) and competitive pressures in cloud services. Current valuation metrics (P/E 21.95, P/S 5.53) appear reasonable given growth prospects, but investors should monitor execution on AI initiatives and cash flow sustainability given substantial capital expenditures.